{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:46:05Z","timestamp":1787503565442,"version":"build-2736575974"},"reference-count":36,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMJ"],"DOI":"10.4274\/mmj.galenos.2025.48830","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:17:01Z","timestamp":1767165421000},"source":"Crossref","is-referenced-by-count":2,"title":["Serum Interleukin-40 and Soluble CD40 Ligand as Complementary Biomarkers for Disease Activity in Multiple Sclerosis Patients"],"prefix":"10.4274","author":[{"given":"Mustafa Ziyad","family":"NEAMAH","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inas K","family":"SHARQUIE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheyath","family":"AL GAWWAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/cimb45020094","article-title":"Multiple sclerosis: inflammatory and neuroglial aspects","volume":"45","author":"Papiri","year":"2023","unstructured":"1. Papiri G, D'Andreamatteo G, Cacchi\u00f2 G, et al. Multiple sclerosis: inflammatory and neuroglial aspects. Curr Issues Mol Biol. 2023;45:1443-70.","journal-title":"Curr Issues Mol Biol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.32007\/jfacmedbagdad.584288","article-title":"MicroRNAs (20a, 146a, 155, and 145) expressions in a sample of Iraqi patients with multiple scle-rosis","volume":"58","author":"Aljawadi","year":"2016","unstructured":"2. Aljawadi ZA, Al-Derzi AR, Abdul-Majeed BA, Almahdawi AM. MicroRNAs (20a, 146a, 155, and 145) expressions in a sample of Iraqi patients with multiple scle-rosis. J Fac Med Baghdad. 2016;58:371-7.","journal-title":"J Fac Med Baghdad"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.32007\/jfacmedbagdad.6311776","article-title":"Paediatric multiple sclerosis: a case report of missed and dismissed diagnosis","volume":"63","author":"nw","year":"2021","unstructured":"3. Saadi nw, Fahad QA. Paediatric multiple sclerosis: a case report of missed and dismissed diagnosis. J Fac Med Baghdad. 2021;63:36-9.","journal-title":"J Fac Med Baghdad"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"101947","DOI":"10.1016\/j.smim.2025.101947","article-title":"The role of the adaptive immune system in the initiation and persistence of multiple sclerosis","volume":"78","author":"AM","year":"2025","unstructured":"4. Afzali AM, Korn T. The role of the adaptive immune system in the initiation and persistence of multiple sclerosis. Semin Immunol. 2025;78:101947.","journal-title":"Semin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.neuroscience.2024.12.029","article-title":"A review on multiple sclerosis: unravelling the complexities of pathogenesis, progression, mecha-nisms and therapeutic innovations","volume":"567","author":"Rida Zainab","year":"2025","unstructured":"5. Rida Zainab S, Zeb Khan J, Khalid Tipu M, Jahan F, Irshad N. A review on multiple sclerosis: unravelling the complexities of pathogenesis, progression, mecha-nisms and therapeutic innovations. Neuroscience. 2025;567:133-49.","journal-title":"Neuroscience"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Paul A, Comabella M, Gandhi R. Biomarkers in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9:a029058.","DOI":"10.1101\/cshperspect.a029058"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/diagnostics15091178","article-title":"Neurodegenerative biomarkers in multiple sclerosis: at the interface between research and clinical practice","volume":"15","author":"Ciubotaru","year":"2025","unstructured":"7. Ciubotaru A, Smihor MI, Grosu C, et al. Neurodegenerative biomarkers in multiple sclerosis: at the interface between research and clinical practice. Diagnostics (Basel). 2025;15:1178.","journal-title":"Diagnostics (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"201436","DOI":"10.1016\/j.humgen.2025.201436","article-title":"Systematic identification of molecular bi-omarkers and drug candidates targeting MAPK3 in multiple sclerosis","volume":"45","author":"Khan","year":"2025","unstructured":"8. Khan B, Sartaj R, Rahiyab M, et al. Systematic identification of molecular bi-omarkers and drug candidates targeting MAPK3 in multiple sclerosis. Hum Gene (Amst). 2025;45:201436.","journal-title":"Hum Gene (Amst)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/neurolint17040056","article-title":"Neurofilament light chain and multiple sclerosis: building a neurofoundational model ofbBiomarkers and diagnosis","volume":"17","author":"Aburashed","year":"2025","unstructured":"9. Aburashed R, Eghzawi A, Long D, Pace R, Madha A, Cote J. Neurofilament light chain and multiple sclerosis: building a neurofoundational model ofbBiomarkers and diagnosis. Neurol Int. 2025;17:56.","journal-title":"Neurol Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"102810","DOI":"10.1016\/j.msard.2021.102810","article-title":"Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI","volume":"50","author":"Saraste","year":"2021","unstructured":"10. Saraste M, Bezukladova S, Matilainen M, et al. Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI. Mult Scler Relat Disord. 2021;50:102810.","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00415-025-13231-9","article-title":"Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discon-tinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)","volume":"272","author":"Fung","year":"2025","unstructured":"11. Fung WH, Wessels MHJ, Coerver EME, et al. Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discon-tinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS). J Neurol. 2025;272:530.","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"996469","DOI":"10.3389\/fimmu.2022.996469","article-title":"Autoreactive lymphocytes in multiple sclerosis: patho-genesis and treatment target","volume":"13","author":"Liu","year":"2022","unstructured":"12. Liu R, Du S, Zhao L, et al. Autoreactive lymphocytes in multiple sclerosis: patho-genesis and treatment target. Front Immunol. 2022;13:996469.","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Fissolo N, Pappolla A, Rio J, et al. Serum levels of CXCL13 are associated with teriflunomide response in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;10:e200050.","DOI":"10.1212\/NXI.0000000000200050"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"9320802","DOI":"10.1155\/2017\/9320802","article-title":"Serum glutamate Is a predictor for the diagnosis of multiple sclerosis","volume":"2017","author":"Gawwam G","year":"2017","unstructured":"14. Al Gawwam G, Sharquie IK. Serum glutamate Is a predictor for the diagnosis of multiple sclerosis. ScientificWorldJournal. 2017;2017:9320802.","journal-title":"ScientificWorldJournal"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5222\/mmj.2020.48265","article-title":"Serum glial fibrillary acidic protein: a sur-rogate marker of the activity of multiple sclerosis","volume":"35","author":"Sharquie","year":"2020","unstructured":"15. Sharquie IK, Gawwam GA, Abdullah SF. Serum glial fibrillary acidic protein: a sur-rogate marker of the activity of multiple sclerosis. Medeni Med J. 2020;35:212-8.","journal-title":"Medeni Med J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"117471","DOI":"10.1016\/j.cca.2023.117471","article-title":"Biochemical bi-omarkers for multiple sclerosis","volume":"548","author":"Maroto-Garc\u00eda","year":"2023","unstructured":"16. Maroto-Garc\u00eda J, Mart\u00ednez-Escribano A, Delgado-Gil V, et al. Biochemical bi-omarkers for multiple sclerosis. Clin Chim Acta. 2023;548:117471.","journal-title":"Clin Chim Acta"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/imm.13198","article-title":"The role of B cells in the immunopatho-genesis of multiple sclerosis","volume":"160","author":"Gharibi","year":"2020","unstructured":"17. Gharibi T, Babaloo Z, Hosseini A, et al. The role of B cells in the immunopatho-genesis of multiple sclerosis. Immunology. 2020;160:325-35.","journal-title":"Immunology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/25785826.2021.1952543","article-title":"B-cell depletion therapy for multiple sclerosis","volume":"45","author":"Miyazaki","year":"2022","unstructured":"18. Miyazaki Y, Niino M. B-cell depletion therapy for multiple sclerosis. Immunol Med. 2022;45:54-62.","journal-title":"Immunol Med"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Dabbagh-Gorjani F. A Comprehensive review on the role of interleukin-40 as a bi-omarker for diagnosing inflammatory diseases. Autoimmune Dis. 2024;2024:3968767.","DOI":"10.1155\/2024\/3968767"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.4049\/jimmunol.1700534","article-title":"Identification of IL-40, a Novel B Cell-Associated Cytokine","volume":"199","author":"Catalan-Dibene","year":"2017","unstructured":"20. Catalan-Dibene J, Vazquez MI, Luu VP, et al. Identification of IL-40, a Novel B Cell-Associated Cytokine. J Immunol. 2017;199:3326-35.","journal-title":"J Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.jtauto.2025.100288","article-title":"The role of soluble CD40L in autoimmune diseases","volume":"10","author":"Mabrouk","year":"2025","unstructured":"21. Mabrouk M, Wahnou H, Merhi Y, Abou-Saleh H, Guessous F, Zaid Y. The role of soluble CD40L in autoimmune diseases. J Transl Autoimmun. 2025;10:100288.","journal-title":"J Transl Autoimmun"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ejr.2022.07.007","article-title":"Diagnostic potential of interleukin-40 (IL-40) in rheumatoid arthritis patients","volume":"44","author":"Ghuraibawi Z","year":"2022","unstructured":"22. Ag Al Ghuraibawi Z, Sharquie IK, Gorial FI. Diagnostic potential of interleukin-40 (IL-40) in rheumatoid arthritis patients. Egypt Rheumatol. 2022;44:377-80.","journal-title":"Egypt Rheumatol"},{"key":"ref22","unstructured":"23. Al Rubaye AM, Sharquie IK, Gorial FI. Serum interleukin 40: an innovative diagnos-tic biomarker for patients with systemic lupus erythematosus. Med J Malaysia. 2023;78:609-15."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Tian S, Wang Y, Wan J, Yang M, Fu Z. Co-stimulators CD40-CD40L, a potential immune-therapy target for atherosclerosis: A review. Medicine (Baltimore). 2024;103:e37718.","DOI":"10.1097\/MD.0000000000037718"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3389\/fimmu.2017.01791","article-title":"The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis","volume":"8","author":"SABM","year":"2017","unstructured":"25. Aarts SABM, Seijkens TTP, van Dorst KJF, Dijkstra CD, Kooij G, Lutgens E. The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Front Immunol. 2017;8:1791.","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"11795735211050712","DOI":"10.1177\/11795735211050712","article-title":"Elevated sCD40L in Secondary progressive multiple sclerosis in comparison to non-progressive benign and relapsing remitting multi-ple sclerosis","volume":"13","author":"Wu","year":"2021","unstructured":"26. Wu Q, Wang Q, Yang J, et al. Elevated sCD40L in Secondary progressive multiple sclerosis in comparison to non-progressive benign and relapsing remitting multi-ple sclerosis. J Cent Nerv Syst Dis. 2021;13:11795735211050712.","journal-title":"J Cent Nerv Syst Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","unstructured":"27. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162-73.","journal-title":"Lancet Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1034056","DOI":"10.3389\/fneur.2022.1034056","article-title":"Rebaseline no evidence of disease ac-tivity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population","volume":"13","author":"Simonsen","year":"2022","unstructured":"28. Simonsen CS, Flemmen H\u00d8, Broch L, et al. Rebaseline no evidence of disease ac-tivity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population. Front Neurol. 2022;13:1034056.","journal-title":"Front Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"6271","DOI":"10.1007\/s10072-022-06276-5","article-title":"Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis","volume":"43","author":"Pastor Bandeira","year":"2022","unstructured":"29. Pastor Bandeira I, de Almeida Franzoi AE, Murillo Wollmann G, et al. Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis. Neurol Sci. 2022;43:6271-8.","journal-title":"Neurol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with Frex-alimab in Multiple Sclerosis","volume":"390","author":"Vermersch","year":"2024","unstructured":"30. Vermersch P, Granziera C, Mao-Draayer Y, et al. Inhibition of CD40L with Frex-alimab in Multiple Sclerosis. N Engl J Med. 2024;390:589-600.","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jneuroim.2016.08.015","article-title":"Serum concentration of CD40L is elevated in in-flammatory demyelinating diseases","volume":"299","author":"Zhong","year":"2016","unstructured":"31. Zhong X, Wang H, Ye Z, et al. Serum concentration of CD40L is elevated in in-flammatory demyelinating diseases. J Neuroimmunol. 2016;299:66-9.","journal-title":"J Neuroimmunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.omtm.2022.04.011","article-title":"Treatment of experimental autoimmune encepha-lomyelitis using AAV gene therapy by blocking T cell costimulatory pathways","volume":"25","author":"Zhong","year":"2022","unstructured":"32. Zhong C, Chen Z, Xia Y, et al. Treatment of experimental autoimmune encepha-lomyelitis using AAV gene therapy by blocking T cell costimulatory pathways. Mol Ther Methods Clin Dev. 2022;25:461-75.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13075-025-03570-3","article-title":"Serum IL-40 is elevated in systemic sclerosis and is linked to disease activity, gastrointestinal involvement, immune regulation and fibrotic processes","volume":"27","author":"Navr\u00e1tilov\u00e1","year":"2025","unstructured":"33. Navr\u00e1tilov\u00e1 A, Oresk\u00e1 S, W\u00fcnsch H, et al. Serum IL-40 is elevated in systemic sclerosis and is linked to disease activity, gastrointestinal involvement, immune regulation and fibrotic processes. Arthritis Res Ther. 2025;27:119.","journal-title":"Arthritis Res Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"745523","DOI":"10.3389\/fimmu.2021.745523","article-title":"IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituxi-mab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis","volume":"12","author":"Navr\u00e1tilov\u00e1","year":"2021","unstructured":"34. Navr\u00e1tilov\u00e1 A, Andr\u00e9s Cerezo L, Hulejov\u00e1 H, et al. IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituxi-mab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis. Front Immunol. 2021;12:745523.","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.3390\/ijms23084115","article-title":"CD40-CD40L in Neurological Disease","volume":"23","author":"Ots","year":"2022","unstructured":"35. Ots HD, Tracz JA, Vinokuroff KE, Musto AE. CD40-CD40L in Neurological Disease. Int J Mol Sci. 2022;23:4115.","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"104789","DOI":"10.1016\/j.ebiom.2023.104789","article-title":"Cross-talk between B cells, microglia and macro-phages, and implications to central nervous system compartmentalized inflam-mation and progressive multiple sclerosis","volume":"96","author":"Touil","year":"2023","unstructured":"36. Touil H, Li R, Zuroff L, et al. Cross-talk between B cells, microglia and macro-phages, and implications to central nervous system compartmentalized inflam-mation and progressive multiple sclerosis. EBioMedicine. 2023;96:104789.","journal-title":"EBioMedicine"}],"container-title":["Medeniyet Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:04:25Z","timestamp":1775541865000},"score":1,"resource":{"primary":{"URL":"https:\/\/medeniyetmedicaljournal.org\/articles\/doi\/MMJ.galenos.2025.48830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":36,"URL":"https:\/\/doi.org\/10.4274\/mmj.galenos.2025.48830","relation":{},"ISSN":["2149-2042"],"issn-type":[{"value":"2149-2042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}